Industry leading technologies and services
OXGENE's XLenti™ production system builds on our considerable expertise in cell line development and plasmid engineering. Based on our widely recognised SnapFast™ plasmid technology, our XLenti™ platform includes an optimised plasmid system that delivers improved yield, quality and safety, while our manufacture-ready suspension-mode lentiviral packaging and producer cell lines enable large scale lentiviral production. This system maximises process reproducibility and reduces manufacturing costs for clinical and commercial cell therapy manufacture.
We offer expert cloning and engineering services to customise and optimise plasmids for expression of your gene of interest. Our process development services optimise for pre-clinical lentiviral manufacture in our ISO:9001 accredited lab, and we manufacture up to 10L scale, before assisting technology transfer to your own facilities or CMO.
XLenti™ transient production
Our optimised third generation packaging plasmids and clonal HEK293 cell line provide enhanced safety and increased lentiviral yield.
XLenti™ packaging and producer cell lines
Stable clonal packaging and producer cell lines offer easy scale up, reduced cost of goods and reduced process complexity.
We know that as cell therapy pioneers, you need complete confidence in the performance of our technologies once they're transferred to your own facilities. That's why our scientists speak directly to yours, offering ongoing and comprehensive technical support.
Are you ready for GMP manufacture?
WuXi Advanced Therapies is a global Contract Testing, Development and Manufacturing Organization (CTDMO) dedicated to accelerating progress and time to market for cell and gene therapies.INTEGRATED GMP MANUFACTURING AND TESTING